Weekly feed

Week of Aug 16–22, 2026

11 curated updates · reviewed against primary sources

Archive
All Open for comment ONC/ASTP CMS HL7 FHIR HITRUST FDA
High FDA

FDA reclassifies ISH test systems for oncology therapeutics from Class III to Class II

The change lowers regulatory burden for companion diagnostic ISH tests while maintaining safety and effectiveness through special controls. The FDA has issued a final order reclassifying in situ hybridization (ISH) test systems indicated for use with a corresponding approved oncology therapeutic...

High HL7 💬 Comments close in 27 days (Sep 14)

HL7 Opens September 2026 Consensus Ballot for FHIR and Other Standards

Voting is open through September 14, 2026, for the HL7 ballot cycle covering FHIR implementation guides and other consensus standards. HL7 International opened its September 2026 consensus ballot cycle on August 14, 2026, inviting ballot pool members to vote on proposed FHIR implementation guides...

High CMS 💬 Comments close in 56 days (Oct 13)

CMS proposes RAPID coverage pathway for accelerated Medicare device coverage

CMS seeks public comment on a new pathway to expedite Medicare national coverage determinations for innovative medical devices using existing regulatory processes. The Centers for Medicare & Medicaid Services (CMS) has announced a proposed Regulatory Alignment for Predictable and Immediate Device...

Notable CMS

CMS mandatory value-based care programs imposed over $3B in administrative costs on hospitals

A study found four mandatory CMS VBC programs generated substantially higher administrative expenses compared to non-participating hospitals. Researchers analyzing Medicare cost reports determined that four mandatory value-based payment programs administered by CMS were associated with more than...

Notable FDA 💬 Comments close in 59 days (Oct 16)

FDA proposes Class I classification for specific medical device accessories under FDARA

FDA seeks comment on classifying certain accessories as Class I devices, where general controls alone would ensure safety and effectiveness. The Food and Drug Administration (FDA) has published a proposed list of medical device accessories that it believes should be classified as Class I devices...

Notable ONC/ASTP HHS 💬 Comments close in 29 days (Sep 16)

HHS Seeks OMB Clearance for TEFCA Monitoring Feedback Collection

HHS is requesting a three-year generic clearance from OMB to collect customer feedback on TEFCA implementation and agency service delivery. The Office of the National Coordinator for Health IT (ONC) within the Department of Health and Human Services (HHS) has submitted a request to the Office of...

Notable CMS HHS

Milken Institute Report Highlights Reimbursement Hurdles for Women's Health Startups

Limited research and evidence barriers make securing coverage difficult for women's health innovations, requiring early reimbursement planning. A new Milken Institute report cited by MedCity News explains that women's health startups face significant reimbursement challenges due to limited...

Notable HHS Other 💬 Comments close in 48 days (Oct 5)

HHS Proposes Consolidation and Revision of ORR Unaccompanied Alien Child Health Forms with DHS Data Sharing Updates

HHS seeks to streamline health forms for unaccompanied alien children while adding provisions for limited health information sharing with DHS to ensure continuity of care. The Administration for Children and Families (ACF) Office of Refugee Resettlement (ORR) is proposing to restructure its...

Notable FDA 💬 Comments close in 28 days (Sep 15)

FDA Seeks Public Comment on Accreditation Scheme for Conformity Assessment Program

FDA requests 60-day public comment on information collection for its ASCA Program supporting medical device conformity assessment under the Paperwork Reduction Act. The Food and Drug Administration (FDA) has announced a 60-day public comment period for its proposed information collection...

FYI FDA 💬 Comments close in 59 days (Oct 16)

FDA Proposes Downgrading Bladder Cancer Detection Endoscopes from Class III to Class II

FDA seeks to reclassify diagnostic endoscopic light source systems for bladder cancer detection to Class II with special controls, eliminating premarket approval requirements. The FDA is proposing to reclassify diagnostic endoscopic light source systems (product code OAY) from Class III...